Table 5. Metastatic compromise in non-SLN and percent of modifications to phase pN2 and pN3, in patients with MM and SMM, according to subtypes and tumour size (n = 44 patients).

			Phase N post ALND
Phase N pre ALND	With ALND	nonSLN+	pN1a	pN2	pN3	% modification	p*
LUMINAL	41	12	6	1	0	18.6
Tu ≤ 2 cm	25	4	1	1	0	8.0
Tu > 2 cm	16	7	5	0	0	31.3	0.05^
NO LUMINAL	3	2	2	0	0	66.7	0.05^
No sorting by size made

NonSLN: non-sentinel lymph node,

MM: micrometastasis,

SMM: submicrometastasis,

ALND: axillary lymph node dissection.

^*p value calculated based on chi-square test.

^{^}Invalid significance calculated by chi-square test, due to low number of cases.